Cara Therapeutics, Inc.
CARA
Rangering i aksjer
#9876
Cara Therapeutics, Inc. is an early-stage biopharmaceutical firm operating... Cara Therapeutics, Inc. is an early-stage biopharmaceutical firm operating primarily within the United States. Its core business involves discovering and commercializing novel drug compounds, with a particular emphasis on addressing itching (pruritus) and pain by selectively modulating kappa opioid receptors. The company's therapeutic pipeline includes potential medicines designed to interact with the body's peripheral nervous system and immune cells. KORSUVA (difelikefalin), an injectable formulation, stands as their flagship product. It is approved for treating moderate-to-severe pruritus linked to chronic kidney disease in adult patients undergoing hemodialysis. Additionally, Cara Therapeutics is advancing an oral version of KORSUVA (difelikefalin) through its pipeline. This oral candidate has successfully completed Phase II clinical trials for relieving pruritus associated with atopic dermatitis and chronic kidney disease not requiring dialysis (NDD-CKD). It is also currently undergoing Phase II evaluation for pruritus related to chronic liver disease (specifically primary biliary cholangitis) and for notalgia paresthetica. The company has established international licensing agreements: one with Maruishi Pharmaceutical Co., Ltd for the development, production, and commercialization of difelikefalin-containing products targeting acute pain and uremic pruritus in Japan, and another with Chong Kun Dang Pharmaceutical Corporation for similar activities concerning difelikefalin products in South Korea. Cara Therapeutics, Inc. was established in 2004 and is headquartered in Stamford, Connecticut.
Aksjekurs
$15.96
Sist synkronisert: 2025-04-15
Markedsverdi
$875.31M
Endring (1 dag)
-4.14%
Endring (1 år)
-0.19%
Land
US
Handel Cara Therapeutics, Inc. (CARA)
Kategori
Healthcare
Markedsverdi av Cara Therapeutics, Inc.(CARA)
Markedsverdi: $875.31M
Per October 2026 har Cara Therapeutics, Inc. en markedsverdi på $875.31M. Dette gjør Cara Therapeutics, Inc. til det 9876th mest verdifulle selskapet i verden basert på markedsverdi ifølge våre data. Markedsverdi er den totale markedsverdien av et børsnotert selskaps utestående aksjer og brukes vanligvis til å måle hvor mye et selskap er verdt.
Markedsverdihistorikk for Cara Therapeutics, Inc. fra 2018 til 2026
CARA sammenlignet med topp 5 mest populære stocks
